A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro

Cardiotoxicity is the main dose-limiting side effect of doxorubicin in the clinic. Being a free radical producer, doxorubicin affects the heart specifically because of its low antioxidant capacity. Among those antioxidants, catalase is present in very low levels in the heart compared to other organs...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Abou El Hassan, M A I, Rabelink, M J W E, van der Vijgh, W J F, Bast, A, Hoeben, R C
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2003
Témata:
Experimental Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2376857/
https://ncbi.nlm.nih.gov/pubmed/14647150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601430
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky